Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Decline in Short Interest

Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 3,236,659 shares, a decrease of 46.9% from the October 15th total of 6,094,189 shares. Currently, 5.9% of the shares of the company are sold short. Based on an average trading volume of 1,127,185 shares, the short-interest ratio is currently 2.9 days.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TARA. Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $26.25.

Get Our Latest Report on TARA

Protara Therapeutics Stock Performance

NASDAQ:TARA opened at $2.53 on Monday. The stock has a market cap of $155.77 million, a price-to-earnings ratio of -1.82 and a beta of 1.54. Protara Therapeutics has a 1 year low of $2.09 and a 1 year high of $7.82. The business has a fifty day moving average of $2.89 and a 200-day moving average of $4.39.

Protara Therapeutics (NASDAQ:TARA – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02. On average, equities research analysts predict that Protara Therapeutics will post -1.37 EPS for the current year.

Hedge Funds Weigh In On Protara Therapeutics

Several large investors have recently bought and sold shares of TARA. Corient Private Wealth LP bought a new stake in shares of Protara Therapeutics during the 2nd quarter worth about $41,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Protara Therapeutics by 22.2% in the first quarter. The Manufacturers Life Insurance Company now owns 13,548 shares of the company’s stock valued at $71,000 after acquiring an additional 2,464 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Protara Therapeutics in the second quarter valued at approximately $69,000. Public Employees Retirement System of Ohio bought a new position in shares of Protara Therapeutics in the second quarter valued at approximately $113,000. Finally, WINTON GROUP Ltd increased its stake in shares of Protara Therapeutics by 16.7% during the second quarter. WINTON GROUP Ltd now owns 32,800 shares of the company’s stock valued at $125,000 after acquiring an additional 4,700 shares during the period. Institutional investors and hedge funds own 38.13% of the company’s stock.

About Protara Therapeutics

(Get Free Report)

Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use. The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease. Protara was formed in 2019 through a merger involving ArTara Therapeutics.

See Also

Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.